Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi... (TF(TM)) designed to upregulate the vascu...)

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

Date:2/5/2008

TF(TM)), designed to upregulate the vascular

endothelial growth factor-A (VEGF-A) gene.

-- Initiation of additional Phase 2 clinical trials of SB-509 in moderate

to severe DN (SB-509-701) and stem cell mobilization (SB-509-703). In

April, Sangamo announced the initiation of a randomized, single-blind,

placebo-controlled, repeat-dosing Phase 2 study designed to evaluate

the clinical safety and effects of repeat administration of SB-509 in

subjects that have moderate to severe DN (SB-509-701). In January

2008, Sangamo announced that it had initiated a randomized,

single-blind, placebo-controlled, multi-center Phase 2 clinical trial

(SB-509-703) in subjects with mild to moderate DN designed to evaluate

the pharmacokinetics of stem cell mobilization into the bloodstream

after treatment with varying doses of SB-509 as well as the clinical

safety and clinical effects of SB-509 administration.

-- Completion of enrollment of Phase 2 clinical trial of SB-509 for mild

to moderate DN (SB-509-601). In December, Sangamo announced that

enrollment was complete in a randomized, double-blind, repeat-dosing,

placebo-controlled, multi-center trial to evaluate SB-509 for the

treatment of mild to moderate DN. The company expects to have data

from this trial in the second half of 2008.

-- Establishment of major alliance with Sigma-Aldrich Corporation. In

July, as part of an agreement to develop and commercialize high value

laboratory research reagents based upon Sangamo's ZFP technology,

Sangamo received an upfront payment of $13.5 million which included

license fees and the purchase of one million shares of Sangamo stock.

Sangamo is also eligible to receive research funding, development and

commercial milestone payments of up to $24 m
'/>"/>

Post Your Comments:

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi...(TF(TM)) designed to upregulate the vascu...),Health